Targeted Next Generation Sequencing Analysis of 1000 individuals with Intellectual Disability by Grozeva, Detelina et al.
RESEARCH ARTICLE
OFFICIAL JOURNAL
www.hgvs.org
Targeted Next-Generation Sequencing Analysis of 1,000
Individuals with Intellectual Disability
Detelina Grozeva,1 † Keren Carss,2,3 † Olivera Spasic-Boskovic,1,4 Maria-Isabel Tejada,5,6 Jozef Gecz,7 Marie Shaw,7
Mark Corbett,7 Eric Haan,7 Elizabeth Thompson,7 Kathryn Friend,8 Zaamin Hussain,1 Anna Hackett,9 Michael Field,9
Alessandra Renieri,10,11 Roger Stevenson,12 Charles Schwartz,12 James A.B. Floyd,2,13 Jamie Bentham,14
Catherine Cosgrove,14 Bernard Keavney,15 Shoumo Bhattacharya,14 Italian X-linked Mental Retardation Project,10,11 ‡ UK10K
Consortium,1,2 ‡ GOLD Consortium,1,7,8,9,12 ‡ Matthew Hurles,2 and F. Lucy Raymond1∗
1Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom; 2The
Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom; 3Department of Haematology,
University of Cambridge, Cambridge CB2 0PT, United Kingdom; 4East Anglian Medical Genetics Service, Addenbrooke’s Hospital, Cambridge, CB2
0QQ, United Kingdom; 5Molecular Genetics Laboratory, Genetics Service, Cruces University Hospital, BioCruces Health Research Institute,
Barakaldo-Bizkaia 48903, Spain; 6Centre for Biomedical Research on Rare Diseases (CIBERER), Madrid 28029, Spain; 7Department of Paediatrics
and Robinson Research Institute, The University of Adelaide, Adelaide, South Australia 5006, Australia; 8SA Pathology, Women’s and Children’s
Hospital, Adelaide, South Australia 5006, Australia; 9Genetics of Learning Disability Service, Hunter Genetics, Waratah, New South Wales 2298,
Australia; 10Medical Genetics, University of Siena, Siena 53100, Italy; 11Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena 53100,
Italy; 12Greenwood Genetic Center, Greenwood, South Carolina 29646; 13The Genome Centre, John Vane Science Centre, Queen Mary University
of London, Charterhouse Square, London EC1M 6BQ, United Kingdom; 14Department of Cardiovascular Medicine, University of Oxford, Wellcome
Trust Centre for Human Genetics, Oxford OX3 7BN, United Kingdom; 15Cardiovascular Research Group, Institute of Cardiovascular Sciences,
University of Manchester, Manchester, M13 9NT, United Kingdom
Communicated by Jacques S. Beckmann
Received 25 March 2015; accepted revised manuscript 21 August 2015.
Published online 9 September 2015 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22901
ABSTRACT: To identify genetic causes of intellectual dis-
ability (ID), we screened a cohort of 986 individuals with
moderate to severe ID for variants in 565 known or can-
didate ID-associated genes using targeted next-generation
sequencing. Likely pathogenic rare variants were found
in 11% of the cases (113 variants in 107/986 indi-
viduals: 8% of the individuals had a likely pathogenic
loss-of-function [LoF] variant, whereas3% had a known
pathogenic missense variant). Variants in SETD5,ATRX,
CUL4B, MECP2, and ARID1B were the most common
causes of ID. This study assessed the value of sequencing
a cohort of probands to provide a molecular diagnosis of
ID, without the availability of DNA from both parents
for de novo sequence analysis. This modeling is clinically
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relevant as 28% of all UK families with dependent chil-
dren are single parent households. In conclusion, to diag-
nose patients with ID in the absence of parental DNA,
we recommend investigation of all LoF variants in known
genes that cause ID and assessment of a limited list of
proven pathogenic missense variants in these genes. This
will provide 11% additional diagnostic yield beyond the
10%–15% yield from array CGH alone.
Hum Mutat 36:1197–1204, 2015. Published 2015 Wiley Period-
icals, Inc.∗
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Introduction
As the quality of antenatal and postnatal care improves, the ge-
netic contribution to intellectual disability (ID) becomes ever more
significant and has emerged as the commonest phenotypic mani-
festation of a constitutional genomic abnormality [Ropers, 2010].
ID is prevalent, despite severely reducing fecundity, due to a high
de novo mutation rate in a wide range of genes leading to rare
Mendelian diseases [Vissers et al., 2010]. Strategies to identify novel
disease causing genes have successfully used de novo trio analysis to
compare the proband’s genome against the parental genomes with
a diagnostic rate of 15%–40% [de Ligt et al., 2012; Rauch et al.,
2012; Gilissen et al., 2014; Hamdan et al., 2014; The Deciphering
Developmental Disorders Study, 2014] and a further 10%–20% di-
agnostic rate using a homozygosity mapping or biallelic variant
analysis strategy [Musante and Ropers, 2014].
C© 2015 The Authors. ∗∗Human Mutation published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
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In single-parent households, which are 28% of households with
dependent children in theUK, as per the 2013 report ofOffice ofNa-
tional Statistics, the lack of readily available DNA from both parents
excludes the use of a proportion of these families in trio analysis.
Nevertheless, analysis of singletons allows detection of novel genes
by analysis of a large number of cases in a replication cohort. This
strategy has been successfully used to identify novel ID-associated
genes where multiple independent loss-of-function (LoF) variants
cause disease (e.g., SETD5; MIM #615743) [Grozeva et al., 2014],
although the interpretation of rare missense variants is challenging
and uncertain.
We have used a large-scale cohort of 986 cases with moderate to
severe ID to inform a strategy and likely diagnostic yield in non-
nuclear families using our current knowledge of the Mendelian
causes of ID.More specifically, we undertook a targeted panel-based
next-generation sequencing (NGS) study to identify rare coding
variants in 565 selected known and candidate ID-associated genes.
The aims of the study were twofold: (i) to estimate the contribution
of variants in known ID-associated genes to disease, and (ii) to
identify novel ID-associated genes.
Materials and Methods
UK10K Cohort
The ID cohort consisted of DNA samples from 996 patients with
moderate-to-severe ID fromtheUK,Australia, Spain,USA, and Italy
with majority of the individuals recruited from the UK (70%). The
appropriate research ethical approvalwas obtained (IRAS03/0/014),
andparents or guardians providedwritten informed consent. A clin-
ical geneticist had assessed the individuals and the cause of the ID
was unknown. The cases had previously been tested negative by rou-
tine diagnostic approaches (i.e., CGHmicroarray analysis at 500 kb
resolution, fragile X [MIM #300624], methylation status of Prader
Willi [MIM #176270]/Angelman syndrome [MIM #105830]). The
gender ratio is 93.8%male and 6.2% female as the sample was orig-
inally collected to assess the contribution of variants in X-linked
disease genes to ID. The ID cohort was a subset of a large replication
study of seven rare diseases and comprised a total of 2,812 individ-
uals who were investigated within the UK10K Project Rare Disease
replication cohort (http://www.uk10k.org/). The studied pheno-
types were 996 cases with ID, 905 cases with congenital heart disease
(CHD); 911 cases comprising ciliopathy, coloboma, neuromuscular
disease, severe insulin resistance, congenital thyroid disease, and 13
internal technical control samples were also included for compari-
son. The analysis reported here only uses results from the ID and
CHD cohorts.
Panel of ID-Associated Genes
A list of known and candidate genes previously associated with
ID was compiled on the basis of current literature, in-house data,
and sequence homology to genes previously implicated in ID.
The full list of the studied 565 genes can be found in Supp.
Table S1. In total, the panel consisted of 253 known and 312
candidate ID-associated genes. To annotate the genes as either
known or candidate, we combined information from DDDG2P
list, Gilissen et al. (2014) and in-house manual curation for
a small proportion of the genes (DDDG2P list is available at
http://decipher.sanger.ac.uk/ddd/ddd_genes). To be considered as
a known cause for ID, the gene had to be annotated as known in
either the DDDG2P list or the Gilissen et al. (2014) study. The rest
of the genes were considered candidate [Gilissen et al., 2014; The
Deciphering Developmental Disorders Study, 2014].
NGS Experiment
Initially, 1,013DNAsamples fromprobandswith IDwere submit-
ted for the NGS analysis, from which 17 samples did not meet the
DNA quality criteria, and a further 10 did not meet downstream
quality control of variant data. The DNA samples were whole-
genome amplified (GenomiPhi V2 DNA Amplification Kit; GE
Healthcare, Little Chalfont, Buckinghamshire, United Kingdom). A
custom-based targeted Agilent SureSelect pull-down array was cre-
ated (AgilentTechnologies, SantaClara,California) and the Illumina
HiSeq 2000 platform was used to sequence the exons of the targeted
regions. Full details of the methods have been previously published
[Grozeva et al., 2014]. The data are based on the GRCh37/hg19
version of the reference genome. The variants were filtered based
on frequency (MAF<1%) in 1000 Genomes, the UK10K twins co-
hort, the NHLBI Exome Sequencing Project (Exome Variant Server
[EVS], http://evs.gs.washington.edu/EVS/), a cohort of 2,172 in-
house whole-exome controls and the UK10K rare replication co-
hort itself (including all phenotypes). We analyzed variants with
predicted functional consequence on the protein (i.e., nonsynony-
mous, inframe indels, and stop codon loss) and variants predicted
to cause LoF of the protein (i.e., nonsense, frameshift, and essential
splice-site variants). Functional annotations were added with the
Ensembl Variant Effect Predictor 2.8 against Ensembl 70 with the
annotation and the corresponding protein consequence reflecting
the most severe impact among the gene transcripts (Supp. Table S2)
[McLaren et al., 2010].Where an individual hadmore than one rare
coding heterozygous mutation in the same gene, this was flagged as
a potential compound heterozygote. Variants were assessed in clini-
cal databases (e.g., the HGMD [Stenson et al., 2014]); evidence was
sought for involvement of the gene in ID (i.e., known or candidate
ID gene), whether the variants were present in the canonical gene
transcript corresponding to the GenBank mRNA NCBI Reference
Sequence, consistency with the expected mode of inheritance, and
the clinical phenotype of the individual. A proportion of the likely
pathogenic variants was either confirmed by Sanger sequence anal-
ysis or by whole-exome sequence analysis using Agilent SureSelect
Human All Exon V5 (Agilent Technologies) from an independent
sample of nonamplified DNA from the probands.
Principal Component Analysis and Cohort Allelic Sums Test
Principal component analysis (PCA) was performed using the R
package SNPRelate [Zheng et al., 2012]. We first identified a list
of appropriate SNPs from the UK10K samples, which were high-
quality, biallelic, polymorphic, common (minor allele frequency
0.05), and not in high-linkage disequilibrium with each other. We
next performed PCA on the UK10K samples, along with a subset
of unrelated HapMap3.3 samples, using the SNPs identified [Alt-
shuler et al., 2010]. To assess whether there was an enrichment of
variants in ID-associated genes in cases with ID as compared with
the CHD sample set, we used the cohort allelic sums test (CAST)
[Morgenthaler and Thilly, 2007].
Results
Overview of ID Cohort
Overall, we observed 9,015 coding nonsynonymous variants
in known and candidate genes passing the quality control and
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frequency filters (MAF<1%) in 996 individuals. Ten individuals had
more than 30 variants per person, whereas the mean number of
variants per person was nine (Supp. Fig. S1). These individuals were
excluded from the subsequent analysis, as they were outliers from
the variant distribution and the variants were likely to be due to
technical artifacts. Following this, the total observed nonsynony-
mous coding variants was 8,466 in 986 individuals (Supp. Table S2).
Of these, 8,011 were classified as missense, inframe indels, or stop
codon losses. The remaining, 455, were classified as LoF (184 were
nonsense, 161 were frameshift, 66 were essential splice donor, and
44 were essential splice acceptor variants, respectively). The mean
number of LoF variants per person was 0.46, whereas the mean
number of missense variants per person was eight (Supp. Figs. S2
and S3). A subset of variants was experimentally validated with
an independent platform. Seventy nine out of the 82 (96%) tested
variants were independently confirmed.
LoF Variants in Known ID-Associated Genes
The primary aim of this study was to estimate the contribution of
LoF andmissense variants in known ID-associated genes to disease.
Altogether, LoF variants considered likely to cause disease were ob-
served in 44 genes out of the 253 known ID-associated genes, in the
ID cohort. This represented 77 variants from the observed 455 LoF
variants, which were assessed as likely to be the cause of disease in
77 individuals (Table 1; Supp. Table S3). Therefore, the overall diag-
nostic rate considering LoF variants in known genes alone is8%of
the whole sample. Approximately 17% (13/77) of the LoF variants
in known genes are present in HGMD (Professional version 2014.3)
[Stenson et al., 2014], whereas the remainder are novel observations
(i.e., variants at these genomic positions have not been observed
in public databases or have been published previously), suggesting
that the full extent of the variation in the recently identified genes
that leads to ID is not fully documented as yet [Tarpey et al., 2009;
Tennessen et al., 2012].
Subsequently, we assessed whether these variants are present in
a recently released large dataset of anonymized exome data from a
range of clinical phenotypes including neuropsychiatric disorders
(Exome Aggregation Consortium (ExAC), Cambridge, MA; URL:
http://exac.broadinstitute.org; accessed November 2014, Supp.
Table S3). Of the 77 variants considered potentially pathogenic, only
five were seen in the ExAC data (with low frequencies 0.002%),
four of which cause autosomal-recessive disease ([PAH; MIM
#612349], [HGSNAT; MIM #610453], [HEXA; MIM #606869], and
(AGA; MIM #613228]) and as expected some of these variants
were seen in a heterozygous state in the control ExAC popula-
tion at low frequencies (four alleles in 122,000 sequenced alleles)
[Tabor et al., 2014]. One variant in KANK1 (MIM #607704) (con-
sidered autosomal-dominant gene), which was annotated as likely
pathogenic, was observed twice in the ExAC data out of the studied
63,000 individuals. These variants remain likely to be pathogenic
in our cases but as the phenotype of the ExAC cases is not recorded,
the significance of the ExAC data is yet unclear.
Enrichment Analysis Yields Additional Insights into
Disease Etiology
In order to estimate the sensitivity with which we have identified
causative LoF variants, and to gain additional insights into disease
etiology, we assessed the enrichment of LoF variants in sequenced
ID-associated genes in our cohort, compared with a comparison
dataset, using the CAST. For comparison, we used the CHD cohort,
which was one of the seven rare disease cohorts in the UK10K
Figure 1. Patients with ID have an enrichment of LoF variants in se-
quenced ID-associated genes comparedwith the CHD cohort. Numbers
in key show number of samples. P values were calculated by one-tailed
Fisher’s exact test.
replication study and was sequenced in the same experimental
pipeline. The ID and CHD cohorts are of similar size, have minimal
overlap in phenotypic spectra, and have no qualitative difference in
population structure (Supp. Fig. S4).
Of the 986 ID samples, 341 (34.6%) had at least one rare LoF vari-
ant in one of the known or candidate 565 sequenced ID-associated
genes, compared with 222/899 (24.7%) in CHD (Fig. 1). This repre-
sents a highly significant enrichment (P = 1.7×10–6). The difference
between the cohorts suggests that10%of the IDcases in this cohort
are caused by LoF variants in the sequenced genes. This is similar to
our actual diagnostic rate of8% for LoF variants, suggesting that
we have identified causal LoFs with high sensitivity.We next applied
more stringent internal variant frequency filters of 0.5%, 0.1%, and
0.05%, the latter of which leaves unique variants only. Regardless of
the filter, the difference between the cohorts is maintained, indicat-
ing that the majority of the LoF variants that cause ID in this cohort
are unique variants. The large majority of LoF variants in the CHD
cohort are unlikely to be pathogenic. For example, in 125 patients,
the variant is present in an external control or in another individual
within the dataset. In further 84 patients, the variants are either in
a candidate gene or in a heterozygous state but in a known gene for
ID, implicated in autosomal-recessive disease.
Next, the LoF variants were categorized according to chromo-
some, variant type, whether the sequenced ID-associated gene is
known to cause disease or is a candidate gene where the evidence
for disease causation is more limited, and whether abnormalities in
the gene cause disease according to a biallelic or a monoallelic mode
of inheritance. We performed the CAST test to evaluate the degree
of enrichment of each of these categories of unique LoF variants in
the ID cohort (Table 2).
LoF single-nucleotide variants (SNVs) in autosomal, known ID-
associated genes with monoallelic mode of inheritance are signif-
icantly enriched in the ID cohort (P = 1.89×10–7). In contrast,
we identified no significant enrichment in known ID-associated
genes with biallelic mode of inheritance (P = 0.057). This is con-
sistent with studies showing that de novo LoF variants are a par-
ticularly frequent cause of ID in Western populations, whereas in
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Table 1. Genes with LoF Variants Classified as Likely Pathogenic, Ranked According to the Number of Observed Variants
Autosomal-dominant inheritance X-linked inheritance Recessive inheritance
Gene N cases Gene N cases Gene N cases
SETD5 7 ATRX 6 HEXA 1 (comp. het. –LoF and a missense variant)
ARID1B 4 CUL4B 5 AGA 1 (homoz.)
GRIN2B 2 IL1RAPL1 3 HGSNAT 1 (comp. het.- LoF [homoz.] and a missense variant)
SCN2A 2 BRWD3 2 PAH 1 (homoz.)
CHD7 2 OPHN1 2
CTNNB1 2 PQBP1 2
KAT6B 2 SLC9A6 2
TCF4 2 UPF3B 2
KANK1 2 ZDHHC9 2
ASXL1 1 NLGN4X 1
MLL2 1 ACSL4 1
SCN8A 1 AFF2 1
EHMT1 1 GPC3 1
FOXP1 1 KDM5C 1
MEF2C 1 MAOA 1
NSD1 1 OFD1 1
PAX6 1 PTCHD1 1
PTEN 1 TSPAN7 1
SHANK2 1 USP9X 1
SETBP1 1
UBE3A 1
N, number; comp. het., compound heterozygous variants; homoz., homozygous variant.
Table 2. Enrichment of Unique LoF Variants in the ID Cohort, Split by Category
Gene category Variant type Frequency ID Frequency CHD P value
Autosome or PAR Known monoallelic
78
LoF SNVs 42/986 (4.26%) 6/899 (0.67%) 1.89×10–7a
LoF indels 13/986 (1.32%) 7/899 (0.78%) 0.180
Synonymous 394/986 (39.96%) 357/899 (39.71%) 0.475
Known biallelic
86
LoF SNVs 43/986 (4.36%) 26/899 (2.89%) 0.057
LoF indels 23/986 (2.33%) 13/899 (1.45%) 0.108
Synonymous 294/986 (29.82%) 258/899 (28.7%) 0.315
Candidate
162
LoF SNVs 52/986 (5.27%) 22/899 (2.45%) 0.001a
LoF indels 26/986 (2.64%) 23/899 (2.56%) 0.516
Synonymous 450/986 (45.64%) 400/899 (44.49%) 0.325
X chromosome
(males only)
Known
89
LoF SNVs 17/925 (1.84%) 0/466 (0%) 9.25×10–4a
LoF indels 14/925 (1.51%) 0/466 (0%) 0.003a
Synonymous 121/925 (22.92%) 41/466 (8.8%) 0.0108
Candidate
150
LoF SNVs 11/925 (1.19%) 2/466 (0.43%) 0.135
LoF indels 4/925 (0.43%) 1/466 (0.21%) 0.457
Synonymous 179/925 (19.35%) 92/466 (19.74%) 0.599
The numerator in the “Frequency ID” and “Frequency CHD” columns show the number of samples in each cohort that have one of more unique variant of the category indicated.
Synonymous variants are included as controls. Variants of all genotypes are included. The number of genes in each category is given in italics.
PAR, pseudo-autosomal region; SNV, single-nucleotide variant; LoF, loss–of-function; ID, intellectual disability cohort; CHD, congenital heart disease cohort. P values calculated
using Fisher’s exact test.
aStatistically significant after Bonferroni correction for multiple testing (P value threshold: 0.005).
populationswith high rate of consanguinity, variants in genes impli-
cated in autosomal-recessive diseases make a significant contribu-
tion [Najmabadi et al., 2011; de Ligt et al., 2012; Rauch et al., 2012;
Gilissen et al., 2014; Hamdan et al., 2014; Musante and Ropers,
2014].
Interestingly, in contrast to autosomal candidate genes (P=0.001),
we identified no significant enrichment on SNVs in X-linked can-
didate genes (P = 0.135). This suggests that, compared with au-
tosomes, a higher proportion of ID-associated genes on the X
chromosome has already been identified. Importantly, as expected,
there is no significant enrichment of synonymous variants in se-
quenced ID-associated genes in the ID cohort compared with CHD
(Table 2).
Missense Variants in Known Genes
In total, 8,011 high-quality rare missense variants (minor al-
lele frequency<1%) were observed in the ID cohort. Assigning
pathogenicity to missense variants is inherently more complex than
for LoF variants as a lower proportion of missense variants af-
fect protein function. This is compounded when the inheritance
of the missense variant is unclear without parental analysis. Xue
et al. (2012) showed that potentially every individual carries large
numbers of rare missense substitutions in their genome [Xue et al.,
2012]. As the studied ID cohort consisted of affected individuals,
without parents, we only analyzed the 400missense variants that had
been reported previously to lead to disease, based on the HGMD
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Table 3. Genes with Missense Variants Classified as Likely
Pathogenic, Ranked According to the Number of Observed Vari-
ants
Autosomal-
dominant
inheritance X-linked inheritance Recessive inheritance
Gene N cases Gene N cases Gene N cases
KRAS 2 MECP2 5 DHCR7 1 (comp. het.)
SLC2A1 2 ATRX 2
ARID1B 1 MED12 2
CHD7 1 DMD 1
GRIN2A 1 GRIA3 1
CNTNAP2 1 PAK3 1
HRAS 1 SMS 1
KCNQ3 1 ZDHHC9 1
MAP2K1 1
NSD1 1
PRRT2 1
PTEN 1
SHOC2 1
STXBP1 1
TUBA1A 1
N, number; comp. het., compound heterozygous variants.
database (Professional release 2014.3) [Stenson et al., 2003; Stenson
et al., 2014]. After manual curation of these 400 missense variants,
only 36 (9%) were classified as likely pathogenic in 33 individuals
in this study (Table 3; Supp. Table S4).
The manual filtering of the 400 variants reported in HGMD in-
cluded removing the following: (i) variants in a gene that is not
reported as causing ID (i.e., candidate genes); (ii) the presence of
the variant in public control databases (NHLBI Exome Sequencing
Project [EVS, http://evs.gs.washington.edu/EVS/]), or internal con-
trol sets, except where the gene causes autosomal-recessive disease;
(iii) variants in genes with autosomal-recessive inheritance if only
one abnormal allele was observed; (iv) NCBI PubMed/literature
search excluded the variant as pathogenic; (v) assessment if other
rare variants (i.e., LoF variants) in the studied individual were more
likely to explain the ID; (vii) pedigree and phenotypic information
predicted a specific mode of inheritance.
In total, 26 genes from the 253 known ID-associated genes (10%)
had a likely pathogenic missense variant (Table 1; Table 3; Supp.
Table S4). Overall, 33 individuals had a potentially disease-causing
missense variant. The total number of observed likely pathogenic
variants was 36, as one individual had compound heterozygousmis-
sense variants in DHCR7 (MIM #602858), another individual had
two missense variants that were potentially pathogenic (in PRRT2
[MIM #614386] and MECP2 [MIM #300005]), whereas another
had two missense variants in SLC2A1 (MIM #138140).
We observed rare missense variants in genes with recessive inher-
itance in the ExAC data (DHCR7 and HGSNAT). With respect to
DHCR7, one of the observed alleles was seen with relatively high
frequency in Asian and African controls in the ExAC data (195
alleles/110,000 alleles in total). As the studied proband in this co-
hort was also of South Asian origin, it is possible that the variant
is a founder-specific risk factor for Smith-Lemli-Opitz syndrome
(MIM #270400) or an incidental nonpathogenic variant [Xue et al.,
2012]. In addition, some of the variants observed in KRAS (MIM
#190070), NSD1 (MIM #606681), SLC2A1 (MIM #138140), and
CNTNAP2 (MIM #604569) were each observed once in 100,000
sequenced alleles in the ExAC data (Supp. Table S4). The clinical
significance of these variants is therefore uncertain, although these
variants in the cases were clinically plausible based on information
from the phenotype case notes.
We applied the CAST test to unique missense variants in an
attempt to estimate the possible contribution of causal missense
variants in our cohort. To enrich for damaging missense variants,
we applied stringent criteria, including only variants that are pre-
dicted to be damaging by each of four scores of predicted damage
(PolyPhen2, SIFT, Condel, andCADD). The used cut off scores were
the following: PolyPhen2 score >0.9, SIFT <0.06, Condel >0.47, and
CADD score (Phred called) >20 [Clifford et al., 2004; Kumar et al.,
2009; Adzhubei et al., 2010; Gonzalez-Perez and Lopez-Bigas, 2011;
Sim et al., 2012; Kircher et al., 2014], and that are absent from ref-
erence datasets. We excluded the samples for which a clearly causal
LoF variant had been identified. 284/900 (31.6%) of the ID cohort
had at least one unique, predicted damaging, missense variant in a
sequenced ID-associated gene, compared with 245/899 (27.3%) in
the CHD cohort. In contrast to LoF variants, this represents only a
slightly significant enrichment (P = 0.025), emphasizing that while
missense variants are likely to be the cause of ID in some cases, their
interpretation is much more challenging than that of LoF variants,
as has previously been shown [Grimm et al., 2015], even following
stringent preselection for likely damaging variants.
LoF Variants in Candidate ID-Associated Genes
The second aim of this study was to identify novel ID-associated
genes, by assessing LoF variants in the 312 candidate ID-associated
genes, to determinewhether therewas sufficient evidence to confirm
the associationof anyof these candidateswithdisease.Wepreviously
successfully employed this strategy to identify SETD5 as an ID-
associated gene [Grozeva et al., 2014]. Here, we sought to determine
whether any other candidate ID-associated genes could similarly
be confirmed. We observed LoF variants in eight candidate ID-
associated genes (Table 4; Supp. Table S3).
We did not observe sufficient number of individuals with LoF
variants in any of these candidate genes in our study alone to justify
reassigning the status of the gene from a candidate to a known
gene status. However, the reporting of novel variants in these genes
provides additional evidence that these are likely to be ID-associated
genes. We collated the current evidence for pathogenicity for these
genes and with the addition of data from this study, it is increasingly
plausible that LoF variants in ASH1L (MIM #607999), ZMYM6
(MIM #613567), PHF10 (MIM #613069), PHIP (MIM #612870),
and WAC (MIM #615049) are sufficient to cause disease in the
affected individuals; FAM120C (MIM #300741) and WNK3 (MIM
#300358) are increasingly likely X-linked ID genes, and further rare
variants in TRMT1 (MIM #611669) increase the evidence that it
is an autosomal-recessive ID gene (Table 4). Additional evidence,
albeit indirect, is that no other potentially pathogenic variants were
observed in any of these individuals in the remaining known ID-
associated genes within the study, although a comprehensive exome
analysis was not performed.Moreover, all of the candidate genes had
negative intolerance scores that suggest intolerance to functional
variation and indicate purifying selection [Petrovski et al., 2013].
Our observation of further rare variants in these candidate genes
provides additional support for the role of these genes in ID. Fur-
thermore, all of these variants were unique to the cohort and were
absent from the control populations (including 122,000 alleles
from the ExAC data). Nonetheless, the identification of additional
cases with rare likely pathogenic variants is required in order to
confirm that these genes are disease causing.
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Table 4. Candidate ID-Associated Genes with LoF Variants and Previous Evidence for Their Involvement in ID
Gene N cases in this
study
N cases previous NGS
studies (total number
of studied individuals,
disorder)
N LoF variants in the
genes in EVS
(N = 6503)/ExAC
(N = 61486)
Mode of in-
heritance
Complementary
supporting
evidence
Residual intolerance
score (percentile)
[Petrovski et al.,
2013]
Article
ZMYM6 2 1 LoF (100 trios, ID) 3/23 AD –0.33 [31] de Ligt et al. (2012)
PHF10 2 1 Lof in an unaffected
sibling (343 trios,
autism)
2/16 AD 6q27 region, one of
four genes in the
smallest region of
overlap, structural
brain
abnormalities
–0.43 [25] Iossifov et al. (2012);
Peddibhotla et al.
(2014)
PHIP 1 1 LoF (100 trios, ID) 2/10 AD –1.23 [5.5] de Ligt et al. (2012)
ASH1L 1 1 missense (100 trios,
ID); 6 missense (765
cases, replication, ID)
1/7 AD –1.80 [2.2] de Ligt et al. (2012)
WAC 1 1 LoF (100 trios, ID) 0/3 AD Eight deletions in
29,085 individuals
with DD
–0.87 [10] Coe et al. (2014); de
Ligt et al. (2012)
FAM120C 1 0/6 X-linked Xp11.22 region, one
of three genes in
the smallest region
of overlap, autism,
ID
–0.14 [44] De Wolf et al. (2014);
Holden and
Raymond (2003);
Qiao et al. (2008)
WNK3 1 0/1 X-linked Xp11.22 region, one
of three genes in
the smallest region
of overlap, autism,
ID
–1.33 [5] Qiao et al. (2008)
TRMT1 1 (comp. het.) 1 LoF (136 families,
ARID)
6/32 AR –0.80 [13] Najmabadi et al.
(2011)
ARID, autosomal-recessive ID; AD, autosomal dominant; AR, autosomal recessive; comp. het., compound heterozygous; N, number; EVS, data from the NHLBI Exome
Sequencing Project (Exome Variant Server, http://evs.gs.washington.edu/EVS/); ExAC, data from the Exome Aggregation Consortium ([ExAC], Cambridge, MA; URL:
http://exac.broadinstitute.org; accessed November 2014).
Discussion
Weperformed targetedNGS analysis of 986 caseswith ID through
a panel of 565 genes, which were either known to cause disease or
were candidate ID-associated genes. We observed 8,466 rare high-
quality variants in 986 individuals with moderate-to-severe ID. On
average, we observed 0.5 LoF rare variants and eight missense rare
variants per person. Rare variants were found in 233 genes out of the
253 known ID-associated genes, illustrating that rarity of a variant
in such a genetically heterogeneous disorder is insufficient to invoke
causality.
The first aim of this study was to estimate the contribution of
variants in known ID-associated genes to disease. After manual cu-
ration of LoF and missense variants in known genes, we were able
to provide a diagnosis for 107/986, 11% of cases (77 individu-
als [8%] had a LoF variant and 30 [3%] cases had a causal
missense variant, whereas three individuals had both a LoF and a
missense variant and hence were counted once). For LoF variants,
the predicted and identified number of causative variants between
the enrichment analysis and the manual curation is consistent, but
for missense variants the analysis was significantly limited by the
lack of parental DNA samples for de novo trio analysis to distin-
guish rare familial from de novo variants. It is therefore likely that
there are additional causal missense variants in this cohort that we
were unable to confidently identify as such.
5% of the studied cohort had a disease-causing variant in a
known X-linked ID gene. This rate is similar to the rate observed
in other recent studies in ID, with the contribution of disease-
causing variants on the X chromosome ranging from 2.5% to
17% [Vissers et al., 2010; de Ligt et al., 2012; Rauch et al., 2012;
Gilissen et al., 2014; Hamdan et al., 2014; Redin et al., 2014; The
Deciphering Developmental Disorders Study, 2014; Yang et al.,
2014].
The most commonly observed genes with LoF variants were
SETD5, ATRX (MIM #300032), CUL4B (MIM #300304), and
ARID1B (MIM #614556). The cohort was ascertained due to the
presence of ID and is relatively biased against recruitment of cases
with a clearly syndromic form of disease. Despite this, the yield of
rare variants in genes normally associated with a distinct syndromic
phenotype was surprising (e.g., in TCF4 [MIM #602272] CHD7
[MIM #608892], ARID1B, etc.), suggesting a broader contribution
of these genes to ID and disease than previously reported. This em-
phasizes the need for non-biased methods for diagnosis. Previous
studies have observed similar phenotypic variability in individu-
als with mutations in known syndromic ID-associated genes (e.g.,
ARID1B, RPS6KA3 [MIM #300075], TCF4, ATRX, SATB2 [MIM
#608148] and SCN8A [MIM #600702]) [Guerrini et al., 2000; Field
et al., 2006; Hoyer et al., 2012; Rauch et al., 2012; Santen et al.,
2012; Santen et al., 2013]. Initial studies implicating a gene in dis-
ease tend to be enriched for the most phenotypically extreme cases
based on clinical ascertainment rather than a cohort representative
of the population. Thismay explain how the initial estimates of pen-
etrance tend to be inflated, whereas the phenotypic heterogeneity
tends to be underestimated [Hoischen et al., 2014]. Therefore, large
sample sets of ID will providemore data to estimate the full scope of
the associated phenotype presentation of mutations in a particular
gene.
The second aim of this study was to attempt to identify any novel
ID-associated genes, within those genes currently classified as can-
didate genes. In this study, the CAST test was underpowered to
detect a significant enrichment of variants in individual genes. This
would require much larger sample sizes, as has also been shown
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by other studies [Liu et al., 2013]. Nevertheless, the finding of an
enrichment of LoF variants in candidate ID-associated genes shows
that some of these variants are probably causative. We found addi-
tional evidence in support of ZMYM6, PHF10, PHIP, ASH1L, WAC
being novel autosomal-dominant ID genes, and FAM120C, WNK3
novel X-linked disease genes and report further rare variants in
TRMT1, an autosomal-recessive gene but the cohort alone did not
provide sufficient evidence to definitively reclassify these candidate
ID-associated genes to known gene status. Only SETD5, which we
previously reported, yielded sufficient number of rare LoF variants
to identify a novel gene fromwithin the cohort alone [Grozeva et al.,
2014]. Assigning causality to a novel candidate gene requires a high
degree of evidence and further sharing of data from similarly large
cohorts of cases with ID is needed to identify the remaining rarer
novel disease causing genes for this highly heterogeneous disorder
[MacArthur et al., 2014].
A recent study of Redin et al. (2014) also argued the benefits of
using targetedNGS approach in a large cohort as a first intention test
for diagnosis of ID. It was shown that variants in some genes were
more frequently observed than others (MECP2,CUL4B, IL1RAPL1,
TCF4, SLC2A1, KDM5C [MIM #314690], etc.). Therefore, the au-
thors concluded that introducing the sequencing of these genes in
clinical practice could be a useful analysis to perform [Redin et al.,
2014]. While our data support the above list, we can add more
genes: SETD5,ARID1B, andATRX. Furthermore, it has been shown
that genes involved in developmental disorders have low-intolerance
scores and thus damaging variants in these genes are not likely to
occur frequently in the general population [Petrovski et al., 2013].
This could justify sequencing these genes as part of a diagnostic
panel when parents could not be recruited for de novo analysis.
The overall diagnostic rate was 11% of the cohort. This yield
is somewhat lower than observed in trio-based ID studies, where
yields ranged from 13% to 28% in exome sequencing analysis and
42% in a recent whole-genome analysis [de Ligt et al., 2012; Rauch
et al., 2012; Gilissen et al., 2014; Hamdan et al., 2014; The Deci-
phering Developmental Disorders Study, 2014]. There are notable
differences in inclusion criteria andmethodology between our study
and the studies above, which make direct comparisons of diagnos-
tic yield between the studies problematic. However, the diagnostic
yield of 11% in our study indicates significant clinical utility of a
proband-only approach where one or both parents are unavailable
for testing. For the identification of novel ID-associated genes, trio
analysis remains the strategy of choice, although the power to de-
tect additional variants in candidate genes in a replication cohort is
illustrated here.
In conclusion, our study shows that targeted NGS of a limited
number of ID-associated genes in probands with moderate-to-
severe ID is a valuable approach and could provide a diagnosis in
11% of the individuals. This rate is comparable to the diagnostic
rate of CGH microarray analysis (14% for copy-number variants
>400kb) [Cooper et al., 2011]. Such analysis could supplement the
currently first tier copy-numbermicroarray test in providing genetic
diagnosis for families where DNA samples from both parents are
not available for de novo analysis.
Acknowledgments
We are indebted to all individuals who participated in the study. This study
made use of data generated by the UK10K Project. We are grateful to Dr.
Caroline Wright for the helpful discussions.
We would like to thank the Exome Aggregation Consortium and the
groups that provided exome variant data for comparison. A full list of con-
tributing groups can be found at http://exac.broadinstitute.org/about.
All variants, considered likely pathogenic (Supp. Tables S3 and S4) have
been submitted to the DECIPHER database (https://decipher.sanger.ac.uk).
Disclosure statement: The authors declare no conflict of interest.
References
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov
AS, Sunyaev SR. 2010. A method and server for predicting damaging missense
mutations. Nat Methods 7:248–249.
Altshuler DM,Gibbs RA, Peltonen L, Altshuler DM,Gibbs RA, Peltonen L, Dermitzakis
E, Schaffner SF,YuF,PeltonenL,Dermitzakis E,BonnenPE, et al. 2010. Integrating
common and rare genetic variation in diverse human populations. Nature 467:52–
58.
Clifford RJ, Edmonson MN, Nguyen C, Buetow KH. 2004. Large-scale analysis of
non-synonymous coding region single nucleotide polymorphisms. Bioinformatics
20:1006–1014.
Coe BP, Witherspoon K, Rosenfeld JA, Van Bon BW, Vulto-Van Silfhout AT, Bosco P,
Friend KL, Baker C, Buono S, Vissers LE, Schuurs-Hoeijmakers JH, Hoischen A,
et al. 2014. Refining analyses of copy number variation identifies specific genes
associated with developmental delay. Nat Genet 46:1063–1071.
Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, Williams C, Stalker
H, Hamid R, Hannig V, Abdel-Hamid H, Bader P, et al. 2011. A copy number
variation morbidity map of developmental delay. Nat Genet 43:838–846.
De Ligt J, Willemsen MH, Van Bon BW, Kleefstra T, Yntema HG, Kroes T, Vulto-Van
Silfhout AT, Koolen DA, De Vries P, Gilissen C, Del Rosario M, Hoischen A, et al.
2012. Diagnostic exome sequencing in persons with severe intellectual disability.
N Engl J Med 367:1921–1929.
De Wolf V, Crepel A, Schuit F, Van Lommel L, Ceulemans B, Steyaert J, Seuntjens
E, Peeters H, Devriendt K. 2014. A complex Xp11.22 deletion in a patient with
syndromic autism: exploration of FAM120C as a positional candidate gene for
autism. Am J Med Genet A 164:3035–3041.
FieldM, Tarpey P, Boyle J, Edkins S, Goodship J, Luo Y,Moon J, Teague J, StrattonMR,
Futreal PA,Wooster R, RaymondFL, et al. 2006.Mutations in theRSK2(RPS6KA3)
gene cause Coffin-Lowry syndrome and nonsyndromic X-linked mental retarda-
tion. Clin Genet 70:509–515.
Gilissen C, Hehir-Kwa JY, Thung DT, Van De Vorst M, Van Bon BW, Willemsen
MH, Kwint M, Janssen IM, Hoischen A, Schenck A, Leach R, Klein R, et al. 2014.
Genome sequencing identifiesmajor causes of severe intellectual disability. Nature
511:344–347.
Gonzalez-Perez A, Lopez-Bigas N. 2011. Improving the assessment of the outcome of
nonsynonymous SNVswith a consensus deleteriousness score, Condel. Am JHum
Genet 88:440–449.
GrimmDG, Azencott CA, Aicheler F, Gieraths U,MacarthurDG, SamochaKE, Cooper
DN, Stenson PD, Daly MJ, Smoller JW, Duncan LE, Borgwardt KM. 2015. The
evaluation of tools used to predict the impact of missense variants is hindered by
two types of circularity. HumMutat 36:513–523.
Grozeva D, Carss K, Spasic-Boskovic O, Parker MJ, Archer H, Firth HV, Park SM,
Canham N, Holder SE, Wilson M, Hackett A, Field M, et al. 2014. De novo
loss-of-function mutations in SETD5, encoding a methyltransferase in a 3p25
microdeletion syndrome critical region, cause intellectual disability. Am J Hum
Genet 94:618–624.
Guerrini R, Shanahan JL, Carrozzo R, Bonanni P, Higgs DR, Gibbons RJ. 2000. A non-
sense mutation of the ATRX gene causing mild mental retardation and epilepsy.
Ann Neurol 47:117–121.
Hamdan FF, Srour M, Capo-Chichi JM, Daoud H, Nassif C, Patry L, Massicotte C,
Ambalavanan A, Spiegelman D, Diallo O, Henrion E, Dionne-Laporte A, et al.
2014. De novomutations in moderate or severe intellectual disability. PLoS Genet
10:e1004772.
Hoischen A, KrummN, Eichler EE. 2014. Prioritization of neurodevelopmental disease
genes by discovery of new mutations. Nat Neurosci 17:764–772.
Holden S, Raymond FL. 2003. The human gene CXorf17 encodes a member of a novel
family of putative transmembrane proteins: cDNA cloning and characterization
of CXorf17 and its mouse ortholog orf34. Gene 318:149–161.
Hoyer J, EkiciAB,Endele S,PoppB,ZweierC,WiesenerA,WohlleberE,DufkeA,Rossier
E, Petsch C, Zweier M, Gohring I, et al. 2012. Haploinsufficiency of ARID1B, a
member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of
intellectual disability. Am J Hum Genet 90:565–572.
Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, Yamrom B, Lee YH,
Narzisi G, Leotta A, Kendall J, Grabowska E, et al. 2012. De novo gene disruptions
in children on the autistic spectrum. Neuron 74:285–299.
Kircher M, Witten DM, Jain P, O’roak BJ, Cooper GM, Shendure J. 2014. A general
framework for estimating the relative pathogenicity of human genetic variants.
Nat Genet 46:310–315.
HUMANMUTATION, Vol. 36, No. 12, 1197–1204, 2015 1203
Kumar P, Henikoff S, Ng PC. 2009. Predicting the effects of coding non-synonymous
variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–
1081.
Liu L, Sabo A, Neale BM, Nagaswamy U, Stevens C, Lim E, Bodea CA, Muzny D, Reid
JG, Banks E, Coon H, Depristo M, et al. 2013. Analysis of rare, exonic variation
amongst subjects with autism spectrum disorders and population controls. PLoS
Genet 9:e1003443.
Macarthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR,
AdamsDR, Altman RB, Antonarakis SE, Ashley EA, Barrett JC, Biesecker LG, et al.
2014. Guidelines for investigating causality of sequence variants in human disease.
Nature 508:469–476.
Mclaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. 2010. Deriving the
consequences of genomic variants with the Ensembl API and SNPEffect Predictor.
Bioinformatics 26:2069–2070.
Morgenthaler S, ThillyWG. 2007. A strategy to discover genes that carrymulti-allelic or
mono-allelic risk for common diseases: a cohort allelic sums test (CAST). Mutat
Res 615:28–56.
Musante L, Ropers HH. 2014. Genetics of recessive cognitive disorders. Trends Genet
30:32–39.
Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, Hosseini
M, Behjati F, Haas S, Jamali P, Zecha A, Mohseni M, et al. 2011. Deep se-
quencing reveals 50 novel genes for recessive cognitive disorders. Nature 478:
57–63.
Peddibhotla S, Nagamani SC, Erez A, Hunter JV, Holder Jr JL, Carlin ME, Bader
PI, Perras HM, Allanson JE, Newman L, Simpson G, Immken L, et al. 2014.
Delineation of candidate genes responsible for structural brain abnormalities in
patients with terminal deletions of chromosome 6q27. Eur J Hum Genet 23:
54–60.
Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. 2013. Genic intolerance
to functional variation and the interpretation of personal genomes. PLoS Genet
9:e1003709.
Qiao Y, Liu X, Harvard C, Hildebrand MJ, Rajcan-Separovic E, Holden JJ, Lewis
ME. 2008. Autism-associated familial microdeletion of Xp11.22. Clin Genet 74:
134–144.
Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, Albrecht B,
Bartholdi D, Beygo J, Di Donato N, Dufke A, Cremer K, et al. 2012. Range
of genetic mutations associated with severe non-syndromic sporadic intellectual
disability: an exome sequencing study. Lancet 380:1674–1682.
RedinC,GerardB, Lauer J,Herenger Y,Muller J,QuartierA,Masurel-Paulet A,Willems
M, Lesca G, El-Chehadeh S, Le Gras S, Vicaire S, et al. 2014. Efficient strategy for
the molecular diagnosis of intellectual disability using targeted high-throughput
sequencing. J Med Genet 51:724–736.
Ropers HH. 2010. Genetics of early onset cognitive impairment. Ann Rev Gen Hum
Genet 11:161–187.
Santen GW, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN,
Peeters EA,Hilhorst-Hofstee Y,WesselsMW,DenHollanderNS, et al. 2012.Muta-
tions in SWI/SNF chromatin remodeling complex geneARID1B causeCoffin-Siris
syndrome. Nat Genet 44:379–380.
SantenGW, Aten E, Vulto-Van Silfhout AT, Pottinger C, Van Bon BW, VanMinderhout
IJ, Snowdowne R, Van Der Lans CA, Boogaard M, Linssen MM, Vijfhuizen L, Van
DerWielenMJ, et al. 2013. Coffin-Siris syndrome and theBAF complex: genotype-
phenotype study in 63 patients. HumMutat 34:1519–1528.
Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. 2012. SIFT web server:
predicting effects of amino acid substitutions on proteins. Nucleic Acids Res
40:W452–W457.
Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S,
Krawczak M, Cooper DN. 2003. Human Gene Mutation Database (HGMD):
2003 update. HumMutat 21:577–581.
Stenson PD,Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. 2014. The Human Gene
MutationDatabase: building a comprehensivemutation repository for clinical and
molecular genetics, diagnostic testing and personalized genomic medicine. Hum
Genet 133:1–9.
TaborHK,AuerPL, Jamal SM,Chong JX,Yu JH,GordonAS,GraubertTA,O’donnellCJ,
Rich SS,NickersonDA, BamshadMJ. 2014. Pathogenic variants formendelian and
complex traits in exomes of 6,517 European and African Americans: implications
for the return of incidental results. Am J Hum Genet 95:183–193.
Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C, O’meara S, Latimer
C, Dicks E, Menzies A, Stephens P, Blow M, et al. 2009. A systematic, large-scale
resequencing screen of X-chromosome coding exons in mental retardation. Nat
Genet 41:535–543.
Tennessen JA, Bigham AW, O’connor TD, Fu W, Kenny EE, Gravel S, Mcgee S, Do R,
Liu X, Jun G, Kang HM, Jordan D, et al. 2012. Evolution and functional impact of
rare coding variation from deep sequencing of human exomes. Science 337:64–69.
The Deciphering Developmental Disorders Study. 2014. Large-scale discovery of novel
genetic causes of developmental disorders. Nature 519:223–228.
Vissers LE, De Ligt J, Gilissen C, Janssen I, Steehouwer M, De Vries P, Van Lier B, Arts
P, Wieskamp N, Del Rosario M, Van Bon BW, Hoischen A, et al. 2010. A de novo
paradigm for mental retardation. Nat Genet 42:1109–1112.
Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, Mort M, Phillips AD, Shaw K, Stenson
PD, Cooper DN, Tyler-Smith C. 2012. Deleterious- and disease-allele prevalence
in healthy individuals: insights from current predictions, mutation databases, and
population-scale resequencing. Am J Hum Genet 91:1022–1032.
Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, Ward P, Braxton A, Wang
M, Buhay C, Veeraraghavan N, Hawes A, et al. 2014. Molecular findings among
patients referred for clinical whole-exome sequencing. JAMA 312:1870–1879.
Zheng X, Levine D, Shen J, Gogarten SM, Laurie C,Weir BS. 2012. A high-performance
computing toolset for relatedness and principal component analysis of SNP data.
Bioinformatics 28:3326–3328.
1204 HUMANMUTATION, Vol. 36, No. 12, 1197–1204, 2015
